Botox still looking good on 30th anniversary

Botox and Botox Cosmetic (onabotulinumtoxinA) hold 14 therapeutic and aesthetic indications combined, more than any other neurotoxin in the world.

Over the past 30 years, more than 100 million vials of Botox and Botox Cosmetic have been manufactured worldwide, providing a trusted and effective treatment option for various therapeutic and aesthetic uses. With two additional FDA approvals this year for therapeutic indications of pediatric upper limb spasticity and pediatric lower limb spasticity, excluding spasticity caused by cerebral palsy, Botox and Botox Cosmetic now proudly hold 14 therapeutic and aesthetic indications combined, reinforcing its leadership in neurotoxin science.

"This incredible milestone underscores our constant focus on innovation and motivates us to further build on our 30 years of research and development efforts for Botox," said Mitchell F. Brin, Senior Vice President Global Drug Development, Chief Scientific Officer, Botox & Neurotoxins. "For three decades, our team has been dedicated to manufacturing and delivering Botox from an unparalleled state-of-the-art facility, abiding by the strictest quality and safety standards. As we now look forward to the next 30 years and beyond, we maintain our commitment to serve patients worldwide across a wide spectrum of diseases and clinical needs."

Botox was first FDA-approved in 1989 for two rare eye muscle disorders – blepharospasm and strabismus in adults, making it the world's first botulinum toxin type A product to be approved. Since then, BOTOX has continued to innovate which has led to the FDA's approval of 11 therapeutic indications, including Chronic Migraine, overactive bladder, incontinence associated with a neurologic condition, cervical dystonia, adult upper limb spasticity, adult lower limb spasticity, severe underarm sweating (axillary hyperhidrosis), and most recently, pediatric upper limb spasticity and pediatric lower limb spasticity, excluding spasticity caused by cerebral palsy.

"Our ongoing collaboration with Allergan and the approval of Botox in 2000 as a first-line treatment for cervical dystonia have been very important to us and have brought hope to the cervical dystonia community," said Art Kessler, President of the Board, Dystonia Medical Research Foundation (DMRF). "We value our shared commitment to raising awareness of the disease, potential treatment options, and the importance of talking to your doctor."

As the first neurotoxin treatment to be approved for aesthetic use, Botox Cosmetic remains a category leader, backed by 17 years of data. Receiving its first FDA approval in 2002 to temporarily improve the appearance of moderate to severe glabellar lines (frown lines between the eyebrows), Botox Cosmetic is also approved for the temporary improvement in the appearance of moderate to severe crow's feet and forehead lines in adults.

With more than 3,900 articles on Botox and Botox Cosmetic published in scientific and medical journals, and over 115 sponsored studies, Botox neurotoxin is one of the most widely researched medicines in the world. Botox continues to be a leader in its category as it carries 28 indications worldwide, with approval for use in 100 different countries.